The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
February 27, 2017
View Complete Issue         Table of Contents 2019 
Atezolizumab (Tecentriq) for Bladder Cancer and NSCLC (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Atezolizumab (Tecentriq) for Bladder Cancer and NSCLC (online only)
February 27, 2017 (Issue: 1515)
The FDA has approved the immune checkpoint inhibitor atezolizumab (Tecentriq – Genentech) for treatment of locally advanced or metastatic urothelial carcinoma and metastatic non-small cell lung cancer (NSCLC) that have progressed during or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Atezolizumab (Tecentriq) for Bladder Cancer and NSCLC (online only)
Article code: 1515g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.